Natera, Inc. (NTRA) Announced Q4 2025 Earnings on February 26, 2026, Reporting "roughly $666 million of revenue in the quarter"

Natera reported fourth quarter 2025 financial results, generating "roughly $666 million of revenue in the quarter," representing "approximately 40% revenue growth over Q4 of 2024." The company achieved a "gross margin of 66.9% in the quarter" and "generated over $107 million in cash flow in 2025." Natera significantly narrowed its operating losses in Q4 and generated net income, supported by a balance sheet with "over $1 billion in cash and securities."
Management highlighted strong volume momentum, stating they "processed about 924,000 tests and set another record for MRD clinical unit growth with 225,000 tests processed in Q4." Notable product announcements included launching the "21-gene fetal focused single-gene NIPT test" and submitting their "first tissue free MRD assay" for colorectal cancer, LATITUDE, to MolDX. Natera also integrated "phased variants" technology into the Signatera platform following the acquisition of Foresight Diagnostics, driving detection thresholds to "unprecedented levels below one-fragmented tumor DNA in a background of 10 million normal copies."
For forward guidance, Natera expects "to generate between $2.62 billion and $2.7 billion in revenues" for 2026. The company guided for "gross margins between 63% and 65%" for the year. Management outlined their strategic approach by stating they are "holding SG&A stable while we make targeted investments in R&D with the expectation that we generate another strong cash flow year in 2026."